当前位置: X-MOL 学术Nat. Rev. Drug. Disc. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Genetic biomarker trumps tissue type in landmark oncology approval
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2017-06-29 , DOI: 10.1038/nrd.2017.128
Asher Mullard

The FDA granted accelerated approval to Merck & Co.'s PD1 blocker pembrolizumab for all cancers with a specific genetic biomarker, regardless of which tissue type is involved. “This is an important first for the cancer community,” said the FDA's Richard Pazdur, acting director of the

中文翻译:

遗传学生物标志物在具有里程碑意义的肿瘤学批准中胜过组织类型

FDA批准了Merck&Co.的PD1阻断剂pembrolizumab加速批准具有特定遗传生物标记的所有癌症,无论涉及哪种组织类型。FDA的理查德·帕兹杜尔(Richard Pazdur)说:“这对癌症界来说是重要的开端。”
更新日期:2017-06-29
down
wechat
bug